Sabiia Seb
PortuguêsEspañolEnglish
Embrapa
        Busca avançada

Botão Atualizar


Botão Atualizar

Ordenar por: 

RelevânciaAutorTítuloAnoImprime registros no formato resumido
Registros recuperados: 3
Primeira ... 1 ... Última
Imagem não selecionada

Imprime registro no formato completo
Contribution of CD4+ T cells to the early mechanisms of ischemia- reperfusion injury in a mouse model of acute renal failure BJMBR
Pinheiro,H.S.; Camara,N.O.S.; Noronha,I.L.; Maugeri,I.L.; Franco,M.F.; Medina,J.O.A.P.; Pacheco-Silva,A..
Renal ischemia-reperfusion (IR) injury is the major cause of acute renal failure in native and transplanted kidneys. Mononuclear leukocytes have been reported in renal tissue as part of the innate and adaptive responses triggered by IR. We investigated the participation of CD4+ T lymphocytes in the pathogenesis of renal IR injury. Male mice (C57BL/6, 8 to 12 weeks old) were submitted to 45 min of ischemia by renal pedicle clamping followed by reperfusion. We evaluated the role of CD4+ T cells using a monoclonal depleting antibody against CD4 (GK1.5, 50 µ, ip), and class II-major histocompatibility complex molecule knockout mice. Both CD4-depleted groups showed a marked improvement in renal function compared to the ischemic group, despite the fact that...
Tipo: Info:eu-repo/semantics/article Palavras-chave: Ischemia-reperfusion; Kidney inflammation; Leukocytes; CD4+ T lymphocytes; Kidney transplantation; Acute renal failure.
Ano: 2007 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2007000400015
Imagem não selecionada

Imprime registro no formato completo
Lamivudine therapy for hepatitis B in renal transplantation BJMBR
Santos,F.R.L.; Haiashi,A.R.; Araújo,M.R.T.; Abensur,H.; Romão Junior,J.E.; Noronha,I.L..
Antiviral therapies are associated with an increased risk of acute rejection in transplant patients. The aim of the present study was to evaluate the efficacy and safety of lamivudine therapy for hepatitis B virus (HBV) infection in renal transplant patients. Six patients were included in this study. They received 150 mg/day of lamivudine during a follow-up period of 24 months. The laboratory tests monitored were HBV DNA, HBsAg, HBeAg, ALT, gamma-GT, serum creatinine and blood cyclosporine levels. The HBV DNA became undetectable in four patients as early as in the third month of treatment. After six months, the viral load was also negative in the other two patients, and remained so until 18 months of follow-up. The medication was well tolerated with no...
Tipo: Info:eu-repo/semantics/other Palavras-chave: Lamivudine; Kidney transplantation; Hepatitis B.
Ano: 2002 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2002000200008
Imagem não selecionada

Imprime registro no formato completo
Microencapsulation and tissue engineering as an alternative treatment of diabetes BJMBR
Maria-Engler,S.S.; Mares-Guia,M.; Correa,M.L.C.; Oliveira,E.M.C.; Aita,C.A.M.; Krogh,K.; Genzini,T.; Miranda,M.P.; Ribeiro,M.; Vilela,L.; Noronha,I.L.; Eliaschewitz,F.G.; Sogayar,M.C..
In the 70's, pancreatic islet transplantation arose as an attractive alternative to restore normoglycemia; however, the scarcity of donors and difficulties with allotransplants, even under immunosuppressive treatment, greatly hampered the use of this alternative. Several materials and devices have been developed to circumvent the problem of islet rejection by the recipient, but, so far, none has proved to be totally effective. A major barrier to transpose is the highly organized islet architecture and its physical and chemical setting in the pancreatic parenchyma. In order to tackle this problem, we assembled a multidisciplinary team that has been working towards setting up the Human Pancreatic Islets Unit at the Chemistry Institute of the University of...
Tipo: Info:eu-repo/semantics/article Palavras-chave: Human pancreatic islets; Pancreas; Extracellular matrix; Stem cells; Islet microencapsulation; Transplantation; Ductal cells.
Ano: 2001 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2001000600001
Registros recuperados: 3
Primeira ... 1 ... Última
 

Empresa Brasileira de Pesquisa Agropecuária - Embrapa
Todos os direitos reservados, conforme Lei n° 9.610
Política de Privacidade
Área restrita

Embrapa
Parque Estação Biológica - PqEB s/n°
Brasília, DF - Brasil - CEP 70770-901
Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco

Valid HTML 4.01 Transitional